Clinical Trials Logo

Tumors clinical trials

View clinical trials related to Tumors.

Filter by:

NCT ID: NCT00060632 Completed - Multiple Myeloma Clinical Trials

Safety Study of Ridaforolimus in Patients With Advanced, Refractory or Recurrent Malignancies (MK-8669-001 AM5)(COMPLETED)

Start date: April 2003
Phase: Phase 1
Study type: Interventional

Phase 1 trial to determine the safety, tolerability and maximum tolerated dose (MTD) of ridaforolimus in patients with refractory or recurrent malignancies, including myeloma and lymphoma.

NCT ID: NCT00024492 Completed - Tumors Clinical Trials

Study of Liposome Encapsulated Mitoxantrone (LEM) in Patients With Advanced Cancer

Start date: August 2001
Phase: Phase 1
Study type: Interventional

Liposome entrapped mitoxantrone (LEM) is a mixture of commercially available mitoxantrone HCL (Novantrone) and a combination of lyophilized lipids. Mitoxantrone, the active agent in the investigational formulation, is a currently marketed chemotherapeutic agent. The rationale for development of liposomal formulations is primarily that of improving the safety profile of the drug, which may permit dose intensification and/or an increase in the cumulative dose that may be administered, resulting in enhanced efficacy. LEM will be given to patients with advanced solid tumors to determine the dose of drug these patients can tolerate. Patients will receive intravenous LEM every 21 days until the disease progresses or toxicity occurs requiring treatment discontinuation. Anti-tumor effects of LEM will be assessed and patients will be evaluated for safety and tolerability.